-

Catalent, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that members of its executive leadership team will virtually present at the SVB Leerink 10th Annual Global Healthcare Conference at 11:20 a.m. ET on February 25, 2021.

A live webcast of the presentation will be accessible at http://investor.catalent.com and will be available for replay following the event.

About Catalent, Inc.

Catalent, Inc. (NYSE: CTLT), an S&P 500® Company, is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 14,000 people, including over 2,400 scientists and technicians, at more than 40 facilities across four continents, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.

More products. Better treatments. Reliably supplied.™

Contacts

Paul Surdez, Catalent, Inc.
(732) 537-6325
investors@catalent.com

Industry:

Catalent, Inc.

NYSE:CTLT
Release Versions
English

Contacts

Paul Surdez, Catalent, Inc.
(732) 537-6325
investors@catalent.com

More News From Catalent, Inc.

Catalent Announces New Board Appointments

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership. Alessandro Maselli, President and CEO, and Board member of Catalent, said “I am excited to work closely with these new Board members as we drive continued growth as an ind...

Catalent, Inc. Reports First Quarter Fiscal 2025 Results

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the first quarter of fiscal 2025, which ended September 30, 2024. “Our first quarter fiscal 2025 results reflect the continued momentum in our business and underscore our customers’ continued confidence in Catalent. Financial highlights in the quarter included double-digit year-over-year growth in both...

Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ to Ardena, a Contract Development and Manufacturing Organization (CDMO) with locations in Belgium, Spain, the Netherlands and Sweden. Financial details of the agreement, which is expected...
Back to Newsroom